Effectiveness of tisagenlecleucel versus real-world standard of care in relapsed/refractory follicular lymphoma.
暂无分享,去创建一个
Lisa V. Hampson | W. Hsu | L. Hampson | Y. Hao | E. Degtyarev | Wen-Hsing Wu | C. Parzynski | Aisha Masood
[1] M. Dreyling,et al. Follicular lymphoma: an update on biology and optimal therapy , 2023, Leukemia & lymphoma.
[2] Sarah F. McGough,et al. An External Control for Mosunetuzumab Using Real-World Data in Follicular Lymphoma in the Third or Subsequent Lines of Systemic Therapy , 2022, Blood.
[3] Sonali M. Smith,et al. Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma , 2022, Blood advances.
[4] L. Sehn,et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. , 2022, The Lancet. Oncology.
[5] Connie Kang. Mosunetuzumab: First Approval , 2022, Drugs.
[6] J. Gribben,et al. Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma , 2022, Blood.
[7] J. Burke. Evolving third-line treatment options for follicular lymphoma. , 2022, Clinical advances in hematology & oncology : H&O.
[8] W. Hsu,et al. Combining the target trial and estimand frameworks to define the causal estimand: an application using real-world data to contextualize a single-arm trial , 2022, Statistics in Biopharmaceutical Research.
[9] J. Concato,et al. External Control Arms in Oncology: Current Use and Future Directions. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] M. Kersten,et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial , 2021, Nature Medicine.
[11] S. Ansell,et al. Tazemetostat: a treatment option for relapsed/refractory follicular lymphoma , 2021, Expert opinion on pharmacotherapy.
[12] G. Salles,et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. , 2021, The Lancet. Oncology.
[13] L. Sehn,et al. Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study , 2021, Blood.
[14] R. Advani,et al. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.
[15] C. Bennette,et al. Emulating Control Arms for Cancer Clinical Trials Using External Cohorts Created From Electronic Health Record‐Derived Real‐World Data , 2021, Clinical pharmacology and therapeutics.
[16] A. Olszewski,et al. Chemotherapy-Free Management of Follicular and Marginal Zone Lymphoma , 2021, Cancer management and research.
[17] K. Keating,et al. Patient-level Factors Associated With the Initial Management of Older Adults Diagnosed With Follicular Lymphoma: A Surveillance, Epidemiology, and End Results-Medicare Analysis. , 2019, Clinical lymphoma, myeloma & leukemia.
[18] A. Freedman,et al. Follicular lymphoma: 2020 update on diagnosis and management , 2019, American journal of hematology.
[19] R. Dada. Diagnosis and management of follicular lymphoma: A comprehensive review , 2019, European journal of haematology.
[20] M. Hernán,et al. The value of explicitly emulating a target trial when using real world evidence: an application to colorectal cancer screening , 2017, European Journal of Epidemiology.
[21] A. Rosenwald,et al. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. , 2016, Blood.
[22] James M Robins,et al. Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. , 2016, American journal of epidemiology.
[23] J. Cerhan,et al. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Bruce D Cheson,et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] F. Angrilli,et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] E. Kimby,et al. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] Elizabeth A Stuart,et al. Matching methods for causal inference: A review and a look forward. , 2010, Statistical science : a review journal of the Institute of Mathematical Statistics.
[28] Antonio J. Grillo-López,et al. Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma , 2002, Expert review of anticancer therapy.
[29] D. Rubin. Using Propensity Scores to Help Design Observational Studies: Application to the Tobacco Litigation , 2001, Health Services and Outcomes Research Methodology.
[30] M. Kenward,et al. An Introduction to the Bootstrap , 2007 .